0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Chronic Obstructive Pulmonary Disorder (COPD) Market Research Report 2023
Published Date: April 2023
|
Report Code: QYRE-Auto-26D2937
Home | Market Reports | Health| Health Conditions| Respiratory Conditions
Global Chronic Obstructive Pulmonary Disorder COPD Market Insights and Forecast to 2028
BUY CHAPTERS

Global Chronic Obstructive Pulmonary Disorder (COPD) Market Research Report 2023

Code: QYRE-Auto-26D2937
Report
April 2023
Pages:88
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Global Chronic Obstructive Pulmonary Disorder (COPD) Market

The global Chronic Obstructive Pulmonary Disorder (COPD) market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Chronic Obstructive Pulmonary Disorder (COPD) is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Chronic Obstructive Pulmonary Disorder (COPD) is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Chronic Obstructive Pulmonary Disorder (COPD) in Hospital is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Chronic Obstructive Pulmonary Disorder (COPD) include GSK, Pfizer, Merck, Novartis, AstraZeneca, Boehringer Ingelheim, Teva Pharmaceuticals, Ario Pharma and Roche, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Chronic Obstructive Pulmonary Disorder (COPD), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chronic Obstructive Pulmonary Disorder (COPD).
The Chronic Obstructive Pulmonary Disorder (COPD) market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Chronic Obstructive Pulmonary Disorder (COPD) market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Chronic Obstructive Pulmonary Disorder (COPD) companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.

Key Segmentations

By Company

  • GSK
  • Pfizer
  • Merck
  • Novartis
  • AstraZeneca
  • Boehringer Ingelheim
  • Teva Pharmaceuticals
  • Ario Pharma
  • Roche
  • Ache
  • Almirall
  • Aquinox Pharmaceuticals
  • Asmacure
  • Astellas Pharma

Segment by Type

  • Short-Acting Bronchodilators
  • Corticosteroids
  • Methylxanthines
  • Long-Acting Bronchodilators
  • Phosphodiesterase-4 Inhibitors
  • Others

Segment by Application

  • Hospital
  • Clinic

By Region

  • North America
  • United States
  • Canada
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Russia
  • Nordic Countries
  • Rest of Europe
  • Asia-Pacific
  • China
  • Japan
  • South Korea
  • Southeast Asia
  • India
  • Australia
  • Rest of Asia
  • Latin America
  • Mexico
  • Brazil
  • Rest of Latin America
  • Middle East & Africa
  • Turkey
  • Saudi Arabia
  • UAE
  • Rest of MEA

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Chronic Obstructive Pulmonary Disorder (COPD) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

Scope of Global Chronic Obstructive Pulmonary Disorder (COPD) Market Report

Report MetricDetails
Report NameGlobal Chronic Obstructive Pulmonary Disorder (COPD) Market
Base Year2022
Forecasted years2023-2029
Forecast unitsUSD
Report coverageRevenue and volume forecast, company share, competitive landscape, growth factors and trends
Geographic regions coveredNorth America, Europe, Asia Pacific, Latin America, Middle East & Africa
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Short-Acting Bronchodilators
1.2.3 Corticosteroids
1.2.4 Methylxanthines
1.2.5 Long-Acting Bronchodilators
1.2.6 Phosphodiesterase-4 Inhibitors
1.2.7 Others
1.3 Market by Application
1.3.1 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Clinic
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Perspective (2018-2029)
2.2 Chronic Obstructive Pulmonary Disorder (COPD) Growth Trends by Region
2.2.1 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Chronic Obstructive Pulmonary Disorder (COPD) Historic Market Size by Region (2018-2023)
2.2.3 Chronic Obstructive Pulmonary Disorder (COPD) Forecasted Market Size by Region (2024-2029)
2.3 Chronic Obstructive Pulmonary Disorder (COPD) Market Dynamics
2.3.1 Chronic Obstructive Pulmonary Disorder (COPD) Industry Trends
2.3.2 Chronic Obstructive Pulmonary Disorder (COPD) Market Drivers
2.3.3 Chronic Obstructive Pulmonary Disorder (COPD) Market Challenges
2.3.4 Chronic Obstructive Pulmonary Disorder (COPD) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Chronic Obstructive Pulmonary Disorder (COPD) Players by Revenue
3.1.1 Global Top Chronic Obstructive Pulmonary Disorder (COPD) Players by Revenue (2018-2023)
3.1.2 Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue Market Share by Players (2018-2023)
3.2 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Chronic Obstructive Pulmonary Disorder (COPD) Revenue
3.4 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Concentration Ratio
3.4.1 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Chronic Obstructive Pulmonary Disorder (COPD) Revenue in 2022
3.5 Chronic Obstructive Pulmonary Disorder (COPD) Key Players Head office and Area Served
3.6 Key Players Chronic Obstructive Pulmonary Disorder (COPD) Product Solution and Service
3.7 Date of Enter into Chronic Obstructive Pulmonary Disorder (COPD) Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Chronic Obstructive Pulmonary Disorder (COPD) Breakdown Data by Type
4.1 Global Chronic Obstructive Pulmonary Disorder (COPD) Historic Market Size by Type (2018-2023)
4.2 Global Chronic Obstructive Pulmonary Disorder (COPD) Forecasted Market Size by Type (2024-2029)
5 Chronic Obstructive Pulmonary Disorder (COPD) Breakdown Data by Application
5.1 Global Chronic Obstructive Pulmonary Disorder (COPD) Historic Market Size by Application (2018-2023)
5.2 Global Chronic Obstructive Pulmonary Disorder (COPD) Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Chronic Obstructive Pulmonary Disorder (COPD) Market Size (2018-2029)
6.2 North America Chronic Obstructive Pulmonary Disorder (COPD) Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2018-2023)
6.4 North America Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Chronic Obstructive Pulmonary Disorder (COPD) Market Size (2018-2029)
7.2 Europe Chronic Obstructive Pulmonary Disorder (COPD) Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2018-2023)
7.4 Europe Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Market Size (2018-2029)
8.2 Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Region (2018-2023)
8.4 Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Chronic Obstructive Pulmonary Disorder (COPD) Market Size (2018-2029)
9.2 Latin America Chronic Obstructive Pulmonary Disorder (COPD) Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2018-2023)
9.4 Latin America Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) Market Size (2018-2029)
10.2 Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2018-2023)
10.4 Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 GSK
11.1.1 GSK Company Detail
11.1.2 GSK Business Overview
11.1.3 GSK Chronic Obstructive Pulmonary Disorder (COPD) Introduction
11.1.4 GSK Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023)
11.1.5 GSK Recent Development
11.2 Pfizer
11.2.1 Pfizer Company Detail
11.2.2 Pfizer Business Overview
11.2.3 Pfizer Chronic Obstructive Pulmonary Disorder (COPD) Introduction
11.2.4 Pfizer Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023)
11.2.5 Pfizer Recent Development
11.3 Merck
11.3.1 Merck Company Detail
11.3.2 Merck Business Overview
11.3.3 Merck Chronic Obstructive Pulmonary Disorder (COPD) Introduction
11.3.4 Merck Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023)
11.3.5 Merck Recent Development
11.4 Novartis
11.4.1 Novartis Company Detail
11.4.2 Novartis Business Overview
11.4.3 Novartis Chronic Obstructive Pulmonary Disorder (COPD) Introduction
11.4.4 Novartis Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023)
11.4.5 Novartis Recent Development
11.5 AstraZeneca
11.5.1 AstraZeneca Company Detail
11.5.2 AstraZeneca Business Overview
11.5.3 AstraZeneca Chronic Obstructive Pulmonary Disorder (COPD) Introduction
11.5.4 AstraZeneca Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023)
11.5.5 AstraZeneca Recent Development
11.6 Boehringer Ingelheim
11.6.1 Boehringer Ingelheim Company Detail
11.6.2 Boehringer Ingelheim Business Overview
11.6.3 Boehringer Ingelheim Chronic Obstructive Pulmonary Disorder (COPD) Introduction
11.6.4 Boehringer Ingelheim Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023)
11.6.5 Boehringer Ingelheim Recent Development
11.7 Teva Pharmaceuticals
11.7.1 Teva Pharmaceuticals Company Detail
11.7.2 Teva Pharmaceuticals Business Overview
11.7.3 Teva Pharmaceuticals Chronic Obstructive Pulmonary Disorder (COPD) Introduction
11.7.4 Teva Pharmaceuticals Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023)
11.7.5 Teva Pharmaceuticals Recent Development
11.8 Ario Pharma
11.8.1 Ario Pharma Company Detail
11.8.2 Ario Pharma Business Overview
11.8.3 Ario Pharma Chronic Obstructive Pulmonary Disorder (COPD) Introduction
11.8.4 Ario Pharma Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023)
11.8.5 Ario Pharma Recent Development
11.9 Roche
11.9.1 Roche Company Detail
11.9.2 Roche Business Overview
11.9.3 Roche Chronic Obstructive Pulmonary Disorder (COPD) Introduction
11.9.4 Roche Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023)
11.9.5 Roche Recent Development
11.10 Ache
11.10.1 Ache Company Detail
11.10.2 Ache Business Overview
11.10.3 Ache Chronic Obstructive Pulmonary Disorder (COPD) Introduction
11.10.4 Ache Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023)
11.10.5 Ache Recent Development
11.11 Almirall
11.11.1 Almirall Company Detail
11.11.2 Almirall Business Overview
11.11.3 Almirall Chronic Obstructive Pulmonary Disorder (COPD) Introduction
11.11.4 Almirall Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023)
11.11.5 Almirall Recent Development
11.12 Aquinox Pharmaceuticals
11.12.1 Aquinox Pharmaceuticals Company Detail
11.12.2 Aquinox Pharmaceuticals Business Overview
11.12.3 Aquinox Pharmaceuticals Chronic Obstructive Pulmonary Disorder (COPD) Introduction
11.12.4 Aquinox Pharmaceuticals Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023)
11.12.5 Aquinox Pharmaceuticals Recent Development
11.13 Asmacure
11.13.1 Asmacure Company Detail
11.13.2 Asmacure Business Overview
11.13.3 Asmacure Chronic Obstructive Pulmonary Disorder (COPD) Introduction
11.13.4 Asmacure Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023)
11.13.5 Asmacure Recent Development
11.14 Astellas Pharma
11.14.1 Astellas Pharma Company Detail
11.14.2 Astellas Pharma Business Overview
11.14.3 Astellas Pharma Chronic Obstructive Pulmonary Disorder (COPD) Introduction
11.14.4 Astellas Pharma Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023)
11.14.5 Astellas Pharma Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
    Table 1. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
    Table 2. Key Players of Short-Acting Bronchodilators
    Table 3. Key Players of Corticosteroids
    Table 4. Key Players of Methylxanthines
    Table 5. Key Players of Long-Acting Bronchodilators
    Table 6. Key Players of Phosphodiesterase-4 Inhibitors
    Table 7. Key Players of Others
    Table 8. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
    Table 9. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
    Table 10. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Region (2018-2023) & (US$ Million)
    Table 11. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Region (2018-2023)
    Table 12. Global Chronic Obstructive Pulmonary Disorder (COPD) Forecasted Market Size by Region (2024-2029) & (US$ Million)
    Table 13. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Region (2024-2029)
    Table 14. Chronic Obstructive Pulmonary Disorder (COPD) Market Trends
    Table 15. Chronic Obstructive Pulmonary Disorder (COPD) Market Drivers
    Table 16. Chronic Obstructive Pulmonary Disorder (COPD) Market Challenges
    Table 17. Chronic Obstructive Pulmonary Disorder (COPD) Market Restraints
    Table 18. Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Players (2018-2023) & (US$ Million)
    Table 19. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Players (2018-2023)
    Table 20. Global Top Chronic Obstructive Pulmonary Disorder (COPD) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chronic Obstructive Pulmonary Disorder (COPD) as of 2022)
    Table 21. Ranking of Global Top Chronic Obstructive Pulmonary Disorder (COPD) Companies by Revenue (US$ Million) in 2022
    Table 22. Global 5 Largest Players Market Share by Chronic Obstructive Pulmonary Disorder (COPD) Revenue (CR5 and HHI) & (2018-2023)
    Table 23. Key Players Headquarters and Area Served
    Table 24. Key Players Chronic Obstructive Pulmonary Disorder (COPD) Product Solution and Service
    Table 25. Date of Enter into Chronic Obstructive Pulmonary Disorder (COPD) Market
    Table 26. Mergers & Acquisitions, Expansion Plans
    Table 27. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Type (2018-2023) & (US$ Million)
    Table 28. Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue Market Share by Type (2018-2023)
    Table 29. Global Chronic Obstructive Pulmonary Disorder (COPD) Forecasted Market Size by Type (2024-2029) & (US$ Million)
    Table 30. Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue Market Share by Type (2024-2029)
    Table 31. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Application (2018-2023) & (US$ Million)
    Table 32. Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue Market Share by Application (2018-2023)
    Table 33. Global Chronic Obstructive Pulmonary Disorder (COPD) Forecasted Market Size by Application (2024-2029) & (US$ Million)
    Table 34. Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue Market Share by Application (2024-2029)
    Table 35. North America Chronic Obstructive Pulmonary Disorder (COPD) Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 36. North America Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2018-2023) & (US$ Million)
    Table 37. North America Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2024-2029) & (US$ Million)
    Table 38. Europe Chronic Obstructive Pulmonary Disorder (COPD) Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 39. Europe Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2018-2023) & (US$ Million)
    Table 40. Europe Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2024-2029) & (US$ Million)
    Table 41. Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
    Table 42. Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Region (2018-2023) & (US$ Million)
    Table 43. Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Region (2024-2029) & (US$ Million)
    Table 44. Latin America Chronic Obstructive Pulmonary Disorder (COPD) Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 45. Latin America Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2018-2023) & (US$ Million)
    Table 46. Latin America Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2024-2029) & (US$ Million)
    Table 47. Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 48. Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2018-2023) & (US$ Million)
    Table 49. Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2024-2029) & (US$ Million)
    Table 50. GSK Company Detail
    Table 51. GSK Business Overview
    Table 52. GSK Chronic Obstructive Pulmonary Disorder (COPD) Product
    Table 53. GSK Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023) & (US$ Million)
    Table 54. GSK Recent Development
    Table 55. Pfizer Company Detail
    Table 56. Pfizer Business Overview
    Table 57. Pfizer Chronic Obstructive Pulmonary Disorder (COPD) Product
    Table 58. Pfizer Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023) & (US$ Million)
    Table 59. Pfizer Recent Development
    Table 60. Merck Company Detail
    Table 61. Merck Business Overview
    Table 62. Merck Chronic Obstructive Pulmonary Disorder (COPD) Product
    Table 63. Merck Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023) & (US$ Million)
    Table 64. Merck Recent Development
    Table 65. Novartis Company Detail
    Table 66. Novartis Business Overview
    Table 67. Novartis Chronic Obstructive Pulmonary Disorder (COPD) Product
    Table 68. Novartis Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023) & (US$ Million)
    Table 69. Novartis Recent Development
    Table 70. AstraZeneca Company Detail
    Table 71. AstraZeneca Business Overview
    Table 72. AstraZeneca Chronic Obstructive Pulmonary Disorder (COPD) Product
    Table 73. AstraZeneca Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023) & (US$ Million)
    Table 74. AstraZeneca Recent Development
    Table 75. Boehringer Ingelheim Company Detail
    Table 76. Boehringer Ingelheim Business Overview
    Table 77. Boehringer Ingelheim Chronic Obstructive Pulmonary Disorder (COPD) Product
    Table 78. Boehringer Ingelheim Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023) & (US$ Million)
    Table 79. Boehringer Ingelheim Recent Development
    Table 80. Teva Pharmaceuticals Company Detail
    Table 81. Teva Pharmaceuticals Business Overview
    Table 82. Teva Pharmaceuticals Chronic Obstructive Pulmonary Disorder (COPD) Product
    Table 83. Teva Pharmaceuticals Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023) & (US$ Million)
    Table 84. Teva Pharmaceuticals Recent Development
    Table 85. Ario Pharma Company Detail
    Table 86. Ario Pharma Business Overview
    Table 87. Ario Pharma Chronic Obstructive Pulmonary Disorder (COPD) Product
    Table 88. Ario Pharma Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023) & (US$ Million)
    Table 89. Ario Pharma Recent Development
    Table 90. Roche Company Detail
    Table 91. Roche Business Overview
    Table 92. Roche Chronic Obstructive Pulmonary Disorder (COPD) Product
    Table 93. Roche Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023) & (US$ Million)
    Table 94. Roche Recent Development
    Table 95. Ache Company Detail
    Table 96. Ache Business Overview
    Table 97. Ache Chronic Obstructive Pulmonary Disorder (COPD) Product
    Table 98. Ache Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023) & (US$ Million)
    Table 99. Ache Recent Development
    Table 100. Almirall Company Detail
    Table 101. Almirall Business Overview
    Table 102. Almirall Chronic Obstructive Pulmonary Disorder (COPD) Product
    Table 103. Almirall Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023) & (US$ Million)
    Table 104. Almirall Recent Development
    Table 105. Aquinox Pharmaceuticals Company Detail
    Table 106. Aquinox Pharmaceuticals Business Overview
    Table 107. Aquinox Pharmaceuticals Chronic Obstructive Pulmonary Disorder (COPD) Product
    Table 108. Aquinox Pharmaceuticals Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023) & (US$ Million)
    Table 109. Aquinox Pharmaceuticals Recent Development
    Table 110. Asmacure Company Detail
    Table 111. Asmacure Business Overview
    Table 112. Asmacure Chronic Obstructive Pulmonary Disorder (COPD) Product
    Table 113. Asmacure Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023) & (US$ Million)
    Table 114. Asmacure Recent Development
    Table 115. Astellas Pharma Company Detail
    Table 116. Astellas Pharma Business Overview
    Table 117. Astellas Pharma Chronic Obstructive Pulmonary Disorder (COPD) Product
    Table 118. Astellas Pharma Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023) & (US$ Million)
    Table 119. Astellas Pharma Recent Development
    Table 120. Research Programs/Design for This Report
    Table 121. Key Data Information from Secondary Sources
    Table 122. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size Comparison by Type (2023-2029) & (US$ Million)
    Figure 2. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Type: 2022 VS 2029
    Figure 3. Short-Acting Bronchodilators Features
    Figure 4. Corticosteroids Features
    Figure 5. Methylxanthines Features
    Figure 6. Long-Acting Bronchodilators Features
    Figure 7. Phosphodiesterase-4 Inhibitors Features
    Figure 8. Others Features
    Figure 9. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size Comparison by Application (2023-2029) & (US$ Million)
    Figure 10. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Application: 2022 VS 2029
    Figure 11. Hospital Case Studies
    Figure 12. Clinic Case Studies
    Figure 13. Chronic Obstructive Pulmonary Disorder (COPD) Report Years Considered
    Figure 14. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size (US$ Million), Year-over-Year: 2018-2029
    Figure 15. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size, (US$ Million), 2018 VS 2022 VS 2029
    Figure 16. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Region: 2022 VS 2029
    Figure 17. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Players in 2022
    Figure 18. Global Top Chronic Obstructive Pulmonary Disorder (COPD) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chronic Obstructive Pulmonary Disorder (COPD) as of 2022)
    Figure 19. The Top 10 and 5 Players Market Share by Chronic Obstructive Pulmonary Disorder (COPD) Revenue in 2022
    Figure 20. North America Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 21. North America Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Country (2018-2029)
    Figure 22. United States Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 23. Canada Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 24. Europe Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 25. Europe Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Country (2018-2029)
    Figure 26. Germany Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 27. France Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 28. U.K. Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 29. Italy Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 30. Russia Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 31. Nordic Countries Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 32. Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 33. Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Region (2018-2029)
    Figure 34. China Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 35. Japan Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 36. South Korea Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 37. Southeast Asia Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 38. India Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 39. Australia Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 40. Latin America Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 41. Latin America Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Country (2018-2029)
    Figure 42. Mexico Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 43. Brazil Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 44. Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 45. Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Country (2018-2029)
    Figure 46. Turkey Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 47. Saudi Arabia Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 48. GSK Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023)
    Figure 49. Pfizer Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023)
    Figure 50. Merck Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023)
    Figure 51. Novartis Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023)
    Figure 52. AstraZeneca Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023)
    Figure 53. Boehringer Ingelheim Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023)
    Figure 54. Teva Pharmaceuticals Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023)
    Figure 55. Ario Pharma Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023)
    Figure 56. Roche Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023)
    Figure 57. Ache Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023)
    Figure 58. Almirall Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023)
    Figure 59. Aquinox Pharmaceuticals Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023)
    Figure 60. Asmacure Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023)
    Figure 61. Astellas Pharma Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023)
    Figure 62. Bottom-up and Top-down Approaches for This Report
    Figure 63. Data Triangulation
    Figure 64. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Leap India

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

RELATED REPORTS

Global Respiratory Assist Devices Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-30T8247
Fri Feb 23 00:00:00 UTC 2024

Add to Cart

Global Bronchiolitis Obliterans Syndrome Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-5U5938
Thu Feb 22 00:00:00 UTC 2024

Add to Cart

Global Table Type Spirometer Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-15D7711
Thu Feb 22 00:00:00 UTC 2024

Add to Cart

Global Non-Cystic Fibrosis Bronchiectasis Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-30S5649
Thu Feb 22 00:00:00 UTC 2024

Add to Cart